

## (19) AUSTRALIAN PATENT OFFICE

(54) Title  
Metastable pharmaceutical compositions

(51)<sup>6</sup> International Patent Classification(s)

**A61K 9/12** (2006.01) 31/137  
**A61K 9/70** (2006.01) 20060101ALI2006031  
**A61K 31/137** 0BMJP **A61K**  
 (2006.01) 31/165  
**A61K 31/165** 20060101ALI2006031  
 (2006.01) 0BMJP **A61K**  
**A61K 31/216** 31/216  
 (2006.01) 20060101ALI2006031  
**A61K 31/4025** 0BMJP **A61K**  
 (2006.01) 31/4025  
**A61K 31/4045** 20060101ALI2006031  
 (2006.01) 0BMJP **A61K**  
**A61K 31/4196** 31/4045  
 (2006.01) 20060101ALI2006031  
**A61K 31/435** 0BMJP **A61K**  
 (2006.01) 31/4196  
**A61K 31/4468** 20060101ALI2006031  
 (2006.01) 0BMJP **A61K**  
**A61K 31/473** 31/435  
 (2006.01) 20060101ALI2005100  
**A61K 31/496** 31/4468  
 (2006.01) 20060101ALI2006031  
**A61K 31/506** 0BMJP **A61K**  
 (2006.01) 31/473  
**A61K 31/565** 20060101ALI2006031  
 (2006.01) 0BMJP **A61K**  
**A61K 31/567** 31/496  
 (2006.01) 20060101ALI2005100  
**A61K 31/568** 8BMEP **A61K**  
 (2006.01) 31/506  
**A61K 47/06** (2006.01) 20060101ALI2006031  
 0BMJP **A61K**  
**A61K 47/10** (2006.01) 31/565  
**A61K 47/32** (2006.01) 20060101ALI2005100  
**A61K 47/38** (2006.01) 8BMEP **A61K**  
**A61M 11/00** 31/567  
 (2006.01) 20060101ALI2006031  
**A61P 5/24** (2006.01) 0BMJP **A61K**  
**A61P 13/10** (2006.01) 31/568  
**A61P 15/10** (2006.01) 20060101ALI2005100  
**A61P 15/18** (2006.01) 8BMEP **A61K**  
**A61P 25/02** (2006.01) 47/06  
**A61P 25/04** (2006.01) 20060101ALI2006031  
**A61P 25/06** (2006.01) 0BMJP **A61K**  
**A61P 25/08** (2006.01) 47/10  
**A61P 25/16** (2006.01) 20060101ALI2005100  
**A61P 25/18** (2006.01) 8BMEP **A61K**  
**A61P 25/22** (2006.01) 47/32  
**A61P 29/00** (2006.01) 20060101ALI2005100  
**A61P 29/02** (2006.01) 8BMEP **A61K**  
 47/38  
**A61K 9/12** 20060101ALI2005100  
 20060101AFI2006031 8BMEP **A61M**  
**0BMJP A61K** 11/00  
**9/70** 20060101ALI2006031  
**20060101ALI2005100** 0BMJP **A61P**  
**8BMEP A61K** 5/24

20060101ALI2006031	25/08
0BMJP	<b>A61P</b>
13/10	0BMJP
20060101ALI2006031	<b>A61P</b>
25/16	
0BMJP	20060101ALI2006031
15/10	0BMJP
20060101ALI2006052	<b>A61P</b>
25/18	
1BMW0	20060101ALI2006031
15/18	0BMJP
20060101ALI2006052	<b>A61P</b>
25/22	
1BMW0	20060101ALI2006052
25/02	1BMW0
20060101ALI2006031	<b>A61P</b>
29/00	
0BMJP	20060101ALI2006031
25/04	0BMJP
20060101ALI2006052	<b>A61P</b>
29/02	
1BMW0	20060101ALI2006031
25/06	0BMJP
20060101ALI2006031	PCT/AU2003/000785
0BMJP	<b>A61P</b>

(21) Application No: 2003240299

(22) Application Date: 2003.06.24

(87) WIPO No: WO04/000361

(30) Priority Data

(31) Number	(32) Date	(33) Country
PS 3173	2002.06.25	AU

(43) Publication Date: 2004.01.06

(43) Publication Journal Date: 2004.03.04

(71) Applicant(s)

Acrux DDS Pty. Ltd.

(72) Inventor(s)

Morgan, Timothy Matthias, Wilkins, Nina Frances, Klose, Kathryn Traci-Jane, Reed, Barry Leonard, Finnin, Barrie Charles

(74) Agent/Attorney

Phillips Ormonde & Fitzpatrick, Level 22 367 Collins Street, Melbourne, VIC, 3000

(56) Related Art

EP 0581587	A2
WO 2000/045795	
WO 2002/017967	A1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
31 December 2003 (31.12.2003)

PCT

(10) International Publication Number  
WO 2004/000361 A1

(51) International Patent Classification?: A61K 47/10,  
9/06, 31/568, 31/565, 31/435, 31/496, A61P 15/10, 15/18,  
25/04, 25/22

Victoria 3041 (AU). FINNIN, Barrie, Charles [AU/AU];  
43 Iris Road, Glen Iris, Victoria 3146 (AU).

(21) International Application Number:  
PCT/AU2003/000785

(74) Agent: PHILLIPS ORMONDE & FITZPATRICK; 367  
Collins Street, Melbourne, Victoria 3000 (AU).

(22) International Filing Date: 24 June 2003 (24.06.2003)

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,  
US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (GH, GM,  
KL, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

Published:  
— with international search report

(30) Priority Data:  
PS 3173 25 June 2002 (25.06.2002) AU

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (for all designated States except US): ACRUX  
DDS PTY LTD [AU/AU]; 103-113 Stanley Street, West  
Melbourne, Victoria 3003 (AU).

(72) Inventors; and

(75) Inventors/Applicants (for US only): WILKINS, Nina,  
Frances [GB/AU]; 35/6 Graham Street, Port Melbourne,  
Victoria 3207 (AU). KLOSE, Kathryn, Traci-June  
[AU/AU]; 21 Sherwood Avenue, Chelsea, Victoria 3196  
(AU). MORGAN, Timothy, Matthias [AU/AU]; 280  
Keeley Lane, Carlton North, Victoria 3054 (AU). REED,  
Barry, Leonard [AU/AU]; 36 Upland Road, Strathmore,

(54) Title: METASTABLE PHARMACEUTICAL COMPOSITIONS

(57) Abstract: The present invention provides a pharmaceutical composition for transdermal delivery comprising; one or more physiologically active agents; and a volatile pharmaceutically acceptable solvent; and wherein the physiological active agent forms a metastable deposit upon evaporation of the volatile solvent.

A1

WO 2004/000361

## METASTABLE PHARMACEUTICAL COMPOSITIONS

### Field of the Invention

5 The present invention relates to compositions for the transdermal delivery of physiologically active agents, to uses of those compositions, and to methods for the transdermal delivery of physiologically active agents.

### Background of the Invention

10 There is a constant need for methods for the safe and effective administration of physiologically active agents. For many medications it is important that the administration regime is as simple and non-invasive as possible in order to maintain a high level of compliance by a patient. Oral administration is one  
15 administration regime that is commonly used because it is a relatively simple regime to follow. However, the oral administration route is also complicated because of complications associated with gastrointestinal irritation and with drug metabolism in the liver.

20 Administration of physiologically active agents through the skin ('transdermal drug delivery') has received increased attention because it not only provides a relatively simple dosage regime but it also provides a relatively slow and controlled route for release of a physiologically active agent into the systemic circulation. However, transdermal drug delivery is complicated by the fact that the  
25 skin behaves as a natural barrier and therefore transport of agents through the skin is a complex mechanism.

Structurally, the skin consists of two principal parts, a relatively thin outermost layer (the 'epidermis') and a thicker inner region (the 'dermis'). The outermost  
30 layer of the epidermis (the 'stratum corneum') consists of flattened dead cells which are filled with keratin. The region between the flattened dead cells of the stratum corneum is filled with lipids which form lamellar phases that are responsible for the natural barrier properties of the skin.

For effective transdermal delivery of a physiologically active agent that is applied to the surface of the skin ('topical application'), the agent must be partitioned firstly from the vehicle into the stratum corneum, it must typically then be diffused within the stratum corneum before being partitioned from the stratum corneum to

5 the viable epidermis and dermis and then into the bloodstream.

To maximise the concentration (thermodynamic activity) of the physiologically active agent in the vehicle it is common for the physiologically active agent to be present as a saturated solution or solid.

10

To overcome some of the problems with transdermal delivery that are associated with transport across the dermal layers ('percutaneous absorption'), physiologically active agents are commonly formulated with incorporation of one or more drug penetration enhancers. For example, aqueous ethanol is commonly

15

used as a vehicle in formulations for topical application and it is known that ethanol can act as a penetration enhancer that can increase the flux of an active agent across the skin because of a solvent drag effect (Berner *et al.*, 1989, *J. Pharm. Sci.*, 78(5), 402-406. Penetration enhancers are known to cause skin irritation in some individuals. In the present invention, ethanol is unlikely to act as

20

a penetration enhancer since, due to the small quantity applied to the skin, the ethanol acts as an intermediary solvent which spreads the drug and enhancer over the skin. Since the drying time of the compositions in question is less than 2 minutes, and *in vitro* weight loss measurements have previously confirmed that the ethanol evaporates off pig skin with a surface temperature of 32 °C within 1

25

minute all that remains is the drug. The short exposure time, less than 2 minutes, of ethanol or similar lipid extracting solvents to the skin is unlikely to alter the barrier function of the skin (Abrams *et al.*, 1993, *J. Invest. Dermatol.*, 101, 609-613).

30

U.S. Patent Number 6444234 combines particular solvents and solute modifiers with skin stabilisers in a transdermal delivery system to form a true solution and thus minimizing irritation to the skin. US Patent Number 6299900 describes the non-occlusive delivery of a physiologically active agent across the skin however, this composition relies on a penetration enhancer to achieve an increased flux.

Compositions formulated without the use of a penetration enhancer are generally not effective enough to deliver significant amounts of the physiological active through the skin. Compositions containing alcohol and acetone vehicles have been used for topical delivery of antibiotics, as seen in U.S. Patent Number 5 6017912, which describes the use of fluoroquinolone in the topical treatment of skin infections and inflammatory conditions. However, such compositions have inherently low permeabilities of the physiological active.

In order to overcome the low permeability, the physiological active must have a 10 maximised thermodynamic activity. According to U.S. Patent Number 6528094, the use of stable shaped particles is particularly well-suited to the fabrication of pharmaceutical formulations, particularly where sustained release and uniform bioavailability are desired. It has been shown that to achieve high permeation rates across the skin, the concentrations of the drug dissolved may need to be 15 high such that it possess a high tendency to crystallise. As a result transdermal patches are often thermodynamically unstable because the drug shows a tendency to recrystallise during storage (Xinghang et al., 1996, Int. J. Pharm., 142(1), 115-119 and Latsch et al., 2003, Eur. J. Pharm. & Biopharm., In Press, Corrected Proof).

20 The use of testosterone in a volatile solvent has been previously disclosed (Wester et al., 1976). However, these compositions which consisted of testosterone dissolved in neat acetone have a propensity to de-fat (remove lipid) the skin under the chronic exposure conditions and therefore suffer from the 25 disadvantage of causing skin irritation as opposed to the compositions that are the subject of this invention.

The discussion of the background to the invention herein is included to explain 30 the context of the invention. This is not to be taken as an admission that any of the material referred to was published, known or part of the common general knowledge in Australia or any other country as at the priority date of any of the claims.

Throughout the description and claims of the specification, the word "comprise"

and variations of the word, such as "comprising" and "comprises", is not intended to exclude other additives, components, integers or steps.

**Summary of the Invention**

5 The present invention arises from the inventor's studies of volatile sprays and aerosols and in particular from the realisation that, for finite dose formulations, appreciable enhancement of percutaneous absorption can be attained from the *in situ* formation of a metastable deposit within the skin using a volatile vehicle,  
10 such as a spray or aerosol.

Previous studies with these type of pharmaceutical compositions have indicated that the rate and extent of partitioning into the skin is already quite efficient with or without added penetration enhancer (Morgan et al., 1998, *J. Pharm. Sci.* 87(10),  
15 1213-1218. The present invention arises, at least in part, from the realisation that an increase in the percutaneous absorption of the physiologically active agent may be achieved by the deliberate formation of a metastable drug *in situ* that has a lower melting point than would be otherwise achieved from the range of crystalline polymorph(s) routinely supplied by the commercial manufacturer. This  
20 reduction in melting point translates to an increase in the diffusion of the drug across the epidermis and dermis and into the bloodstream. To put the invention into practice the present inventor's have found that some combinations of physiologically active agent and volatile solvent form a metastable solid *in situ* when they are applied topically.

25 Accordingly, the present invention provides a composition including:

- one or more physiologically active agents; and
- a volatile pharmaceutically acceptable solvent

wherein the physiologically active agent forms a metastable deposit upon  
30 evaporation of the volatile solvent. The lower melting point metastable deposit arises, at least in part, from either a metastable pseudopolymorph such as an alcohol solvate, a metastable polymorph, a metastable amorphous solid, or a mixture of these. Typically the reduction in melting point (at atmospheric

4A

pressure) provided by the metastable deposit will be in the range of from 1 to 50°C and preferably from 2 to 30°C.

In one aspect, the present invention provides a pharmaceutical composition for transdermal delivery comprising:

- from about 0.1% to about 10% by weight of one or more physiologically active agents; and
- from about 85% to 99.8% by weight of the total composition of a volatile carrier comprising a volatile pharmaceutically acceptable solvent selected from the group consisting of ethanol, isopropanol, chloroform, acetone and mixtures thereof, and optionally, a propellant;

wherein the composition is free of non-volatile penetration enhancers, and wherein the physiological active agent is formulated with the volatile carrier so that the composition forms a metastable deposit comprising the active agent

upon evaporation of the volatile solvent as determined by melting point and DSC analysis.

In another aspect, the present invention provides use of a volatile solvent and a physiologically active agent in the preparation of a spray on transdermal

pharmaceutical composition of the active by formulating with the volatile solvent so that the composition when applied to the skin of a subject forms a metastable deposit of the active agent upon evaporation of the volatile solvent whereby partitioning of the physiologically active agent from the stratum corneum to the viable epidermis is enhanced.

In a further aspect, the present invention provides a method for the transdermal delivery of a physiologically active agent to a subject in need thereof, comprising applying to the skin of the subject a pharmaceutical composition comprising:

- from about 0.1% to about 10% by weight of one or more physiologically active agents; and
- from about 85% to about 99.8% by weight of a volatile carrier comprising one or more volatile pharmaceutically acceptable solvents selected from the group consisting of ethanol, isopropanol, chloroform and acetone, and mixtures thereof, and optionally, a propellant;

wherein the composition is free of non-volatile penetration enhancers and wherein, upon application and evaporation of the volatile solvent, the composition forms a metastable deposit comprising the active agent.

5

In yet a further aspect, the present invention provides a method of treatment or prophylaxis of disease in a subject in need thereof by transdermal administration of a physiologically active agent, comprising applying to the skin of the subject a topical pharmaceutical composition comprising:

10 (i) from about 0.1% to about 10% by weight of one or more physiologically active agents; and

(ii) from about 85% to about 99.8% by weight of a volatile carrier comprising one or more volatile pharmaceutically acceptable solvents selected from the group consisting of ethanol, isopropanol, chloroform and acetone, and

15 mixtures thereof, and optionally a propellant;

wherein the composition is free of non-volatile penetration enhancers and wherein, upon application and evaporation of the volatile solvent, the composition forms a metastable deposit comprising the active agent.

20 Unlike a solid precipitate (e.g. salt derivative of a drug) or a high melting point crystalline polymorph, the metastable deposit is readily partitioned into the skin

upon evaporation of the volatile solvent and rapidly diffuses across the stratum corneum. The formation of the higher melting point crystalline deposits in the skin leads to a higher propensity toward skin irritation and a decrease in percutaneous absorption efficiency (due to the need for greater energy to dissolve the crystal prior to diffusional transport).

5 The metastable deposit also has excellent skin feel and touch when in some instances it may be desirable to rub the metastable deposit into the skin of a human.

10

The composition of the invention is essentially free of penetration enhancers. Penetration enhancers have the effect of increasing skin permeability by reversibly damaging or altering the physicochemical nature of the stratum corneum to reduce its diffusion resistance. Penetration enhancers are generally 15 lipophilic, non-volatile compounds with a molecular weight greater than 100 and a vapour pressure below 10mm Hg at atmospheric pressure and normal skin temperature of 32°C.

20 In addition to providing improved percutaneous absorption efficiency, the composition of the invention may also provide lower irritancy than some other delivery systems such as benzyl alcohol sprays, because the irritating penetration enhancer is removed. Also, the composition of the present invention may avoid problems with crystallisation and/or supersaturation that are encountered with storage of existing type transdermal patches because the 25 pharmaceutical compositions of this invention exist as stable, single phase solutions and hence have no crystalline nature (or polymorphic memory) during their pharmaceutical shelf life. Another advantage of the present invention is the rapid partitioning into the skin from these *in-situ* forming metastable compositions which means the skin can act as a natural crystalline inhibitor for 30 the physiologically active agent, further improving the stability of the metastable deposit within the skin. This leads to consistent and reliable delivery profile of the physiologically active agent over the desired dosage interval, which is typically once every 24 hours.

The present invention also provides a method of delivering a metastable drug formulation to a host, the method including the steps of applying a topical spray composition containing one or more physiologically active agents, and a volatile pharmaceutically acceptable solvent to the skin of the host so that the volatile solvent evaporates to form a metastable deposit containing the active agent.

The present invention further provides a composition for spray application to the skin of a subject for transdermal administration of a physiologically active agent, the composition comprising:

- 10 (i) a physiologically active agent;
- (ii) a volatile pharmaceutically acceptable solvent; and
- (iii) a propellant, preferably a fluoro hydrocarbon;

wherein the composition when applied to the skin as a spray forms a metastable deposit in the skin of the subject.

The invention also provides a spray device for transdermal administration of a physiologically active agent comprising a chamber for maintaining the composition under pressure, a mixture contained within the chamber comprising the physiologically active agent, a pharmaceutically acceptable solvent which is volatile when applied to skin and a propellant which is preferably maintained at least partially in liquid form under pressure within the chamber and valve means for providing delivery of the mixture and wherein the mixture provides a metastable deposit of physiologically active agent on the skin. The propellant is preferably a hydrofluorocarbon such as HFC-134a or HFC-227. HFC-134a is the most preferred propellant. The hydrofluorocarbon propellant is preferably from 15 to 50% by volume of the total pharmaceutical composition and more preferably from 20 to 40% by volume of the total composition.

30 The invention further provides the use of an active agent for manufacture of a medicament for treatment or prophylaxis disease in a subject wherein the composition includes a physiologically active agent and a volatile carrier and is topically applied to the skin of the subject for transdermal administration

wherein the volatile solvent evaporates to form a metastable deposit containing the active agent.

In addition the metastable composition avoids the disadvantage of spray nozzle  
5 blockage seen with existing film-forming sprays or aerosols.

The invention also provides a composition as described above contained in a chamber wherein the propellant is HFC-134a. The volatile solvent and active will preferably provide a single phase solution of the active.

10

As used herein the term 'amorphous' means substantially non-crystalline. It will be appreciated that, unless specified otherwise, the term amorphous includes within its scope a phase that does display some crystallinity.

15 The combination of physiologically active agent and volatile solvent of the present invention is limited functionally to those that together form a metastable deposit with a melting point lower than that seen from the range of crystalline polymorph(s) routinely supplied by the commercial manufacturer or obtained from crystallisation from methanol or chloroform. For this reason it is preferred  
20 that the active agent is relatively non-volatile relative to the volatile solvent so that upon application of the composition to the skin of the host, only the volatile solvent evaporates at physiological temperatures.

In practice, it has been found that the physiologically active agent may be selected  
25 from a range of potent, lipophilic, physiologically active agents with a molecular weight less than 600 Daltons and a melting point less than 200°C with the list including apomorphine, fentanyl, ropinirole, rivastigmine, buspirone, rizatriptan, anticholinergics such as oxybutynin, tolterodine and darifenacin, testosterone, MENT (7-methyl-19-testosterone), ethynodiol, or an pharmaceutically acceptable salt or derivative of any one of the aforementioned.

The drug and solvent generally have the ability to intimately mix, such that the solvent will interact with the crystal face of the drug. Therefore, the drug will

typically have a saturated solubility in the solvent of greater than or equal to 0.05% w/w, more preferably greater than or equal to 0.1% w/w.

Preferably the volatile solvent has a vapour pressure is above 35mm Hg at 5 atmospheric pressure and normal skin temperature of 32°C. The volatile solvent will preferably comprise a lower alcohol. More preferably the volatile solvent will comprise at least 60% by weight of the total volatile solvent component of lower alcohol.

10 Most preferably the volatile solvent component will consist essentially of one or more lower alcohols. The preferred lower alcohols are ethanol, isopropanol and mixture thereof.

15 Conveniently, the composition is a topical spray composition that contains the physiologically active agent and the volatile solvent and the method includes the step of spraying the composition onto the skin of the host to form the metastable deposit containing the physiologically active substance.

20 In each of the above cases the metastable deposit is preferably formed in the epidermis of the host.

#### Brief Description of the Figures

In the accompanying figures:

25 Figure 1 shows a plot of the cumulative amount of drug penetrating across the skin from the metastable composition compared to a saturated solution of drug.

30 Figure 2 gives an example of base DSC profiles before and after evaporation from ethanol.

Figure 3 shows a plot of the melting point of each model drug, before and after evaporation from a volatile solvent after a time period of 24 hours.

5 Figure 4 shows a plot of the diffusion profile for fentanyl through human epidermis, after evaporation from ethanol and isopropyl alcohol.

Detailed Description of the Invention

A benefit of the present invention is that the composition is stable, which means that it is not prone to supersaturation or crystallisation during its pharmaceutical shelf life.

10 This may be contrasted with transdermal patches in which crystallisation of the active agent has presented a problem in the past. Thus the composition of the present invention can be held in a primary container during the shelf life without encountering shelf-life problems of the prior art transdermal patches.

15 The composition of the present invention may contain from about 0.1% to about 10% of the physiologically active agent, and from about 85% to about 99.8% of the volatile solvent.

20 Optionally, the vehicle may have additional pharmaceutical excipients, for example gelling agents, such as CARBOPOL™ (an acrylic acid polymer) and cellulose derivatives.

25 The invention will now be described with reference to the following examples. It is to be understood that the examples are provided by way of illustration of the invention and that they are in no way limiting to the scope of the invention.

**Example 1**

***In situ* formation of metastable drug deposits**

30 The formation of a metastable deposit of drug within the stratum corneum can be expected to increase the penetration of a drug across the skin relative to a

10

saturated solution of a drug or a simple dispersion of the solid drug on the surface of the skin as shown in figure 1 (levels not detected).

**Example 2**

**5 Melting point reduction for various active agents mixed with volatile solvent**

The ability to form a metastable deposit of the drug after evaporation of a volatile solvent can be determined by the reduction in melting point achieved 24

10 hours after solvent evaporation, as shown in figures 2 and 3.

**Materials**

Fentanyl  
 Buspirone  
 Testosterone  
 15 Ethinyl Estradiol (EE2)  
 95% EtOH  
 Isopropyl alcohol (IPA)  
 Chloroform  
 Acetone

20

The active agents chosen represent a diverse range of physicochemical properties as shown in the following table:

**Drugs of Choice – physicochemical properties**

	MW Daltons	LogP	MP
Fentanyl	336.48	3.79	84.0°C
Buspirone	385.51	2.63	103.5°C
Testosterone	288.4	3.01	156.0°C
EE <sub>2</sub>	296.4	3.91	180.8°C

25

**Method**

Various % w/v mixtures of active agent and volatile solvent were prepared. A 10 microlitre aluminium micro-DSC pan was then placed in a 50 microlitre aluminium DSC pan, and 5 microlitre aliquots of each formulation were pipetted

into the 10 microlitre DSC pan. The volatile solvent was allowed to evaporate and further aliquots were re-applied until sufficient residue remained.

The pans were maintained at ambient temperature and 33% relative humidity  
5 for 24 hours. After this time the pans were covered and hermetically sealed. DSC was then performed under a stream of nitrogen and at 10°C/minute and within a temperature range that depended on the drug.

### Results

10 Evaporation by each solvent resulted in melting point modulation (Figure 2). DSC analysis of buspirone after solvent evaporation demonstrated the steadier melting point reduction (Figure 3). In contrast, fentanyl, testosterone and EE2 showed very solvent dependent melting point reductions. In each case, isopropyl alcohol demonstrated the most significant difference in melting point  
15 change when compared to the compound base. Melting point depression is, we have found, an indication that the composition will have an increase in percutaneous absorption. In addition, the stratum corneum may prevent crystallisation, resulting in a solvent deposited metastable solid within the stratum corneum.

20

### Example 3

#### Effect of metastable compositions on percutaneous penetration

The choice of solvent used in a composition can be selected on the basis of the  
25 desired transdermal delivery profile as measured by percutaneous penetration (an example of which is shown in figure 4) in order to achieve the desired pharmacological effect.

The aforementioned examples are not meant to be limiting and it is envisaged that combinations of volatile solvents could also be used to obtain the desired  
30 pharmacological effect; for example on a weight basis.

Ethanol : IPA                    20-80 : 20-80

Ethanol : Acetone

or IPA                    or Chloroform            60-90 : 10-40;

or a mixture thereof.

#### Diffusion Studies

5 Diffusion studies were conducted to determine the delivery profile of metastable compositions across skin.

#### Formulations

Fentanyl in ethanol (1 mole)

10 Fentanyl in isopropyl alcohol (1 mole)

All formulations were prepared by accurately weighing the appropriate amount of physiological active into a volumetric flask and made up to volume with appropriate volatile solvent.

15 Method

*In vitro* diffusion experiments were performed using stainless steel flow-through diffusion cells, using human epidermis maintained at 32°C. The receptor solution consisted of either 10% EtOH in 0.002% NaN<sub>3</sub> or 20% EtOH in 0.002% NaN<sub>3</sub>. Eight cells for each condition were treated with 5 $\mu$ l of appropriate donor 20 phase, each a finite dose that was formulation dependent. Samples were collected at appropriate time points and analysed by high performance liquid chromatography (HPLC).

25

30

Table 1. HPLC conditions for receptor solution analysis.

Parameters	Method	
	Buspirone	Fentanyl
Column	Symmetry C18 (3.9*150mm) 5 $\mu$ m	Symmetry C18 (3.9*150mm) 5 $\mu$ m
Mobile Phase	Line A: 20% AcN in 0.01M KH <sub>2</sub> PO <sub>4</sub> @ pH 2.85nM Line B: 90 % AcN @ pH 2.8	Line A: 5nM TEA (milli-Q), pH 10.9 Line B: 100% AcN
Pump	Isocratic: 70% A 30% B	Gradient: Time %A %B 0 80 20 8.5 63 37 9 80 20 11 80 20
Flow rate	1.0 ml/min	1.0 ml/min
Absorbance	239 nm	210 nm
Injection volume	50 $\mu$ l	50 $\mu$ l
Column Temp.	40 °C	-

### Results

5 Diffusion experiments were performed using fentanyl as a model compound, after ethanol and isopropyl alcohol evaporation.

Fentanyl diffusion profile, through human epidermis, demonstrates a change in delivery profile which is solvent dependent (Figure 5). After evaporation from 10 ethanol, fentanyl showed a sigmoidal, first order diffusion profile indicating that the initial burst across the skin is limited. However, after evaporation from isopropyl alcohol, fentanyl shows a zero order release rate profile. Therefore, the leaving tendency may be modified to suit the desired delivery rate by altering the volatile solvent vehicle.

16 Jan 2008  
2003240299

14

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A pharmaceutical composition for transdermal delivery comprising:
  - from about 0.1% to about 10% by weight of one or more physiologically active agents; and
  - from about 85% to 99.8% by weight of the total composition of a volatile carrier comprising a volatile pharmaceutically acceptable solvent selected from the group consisting of ethanol, isopropanol, chloroform, acetone and mixtures thereof, and optionally, a propellant;
- 5 10 wherein the composition is free of non-volatile penetration enhancers, and wherein the physiological active agent is formulated with the volatile carrier so that the composition forms a metastable deposit comprising the active agent upon evaporation of the volatile solvent as determined by melting point and DSC analysis.
- 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105 1110 1115 1120 1125 1130 1135 1140 1145 1150 1155 1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615 1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675 1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730 1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790 1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845 1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 3000 3005 3010 3015 3020 3025 3030 3035 3040 3045 3050 3055 3060 3065 3070 3075 3080 3085 3090 3095 3100 3105 3110 3115 3120 3125 3130 3135 3140 3145 3150 3155 3160 3165 3170 3175 3180 3185 3190 3195 3200 3205 3210 3215 3220 3225 3230 3235 3240 3245 3250 3255 3260 3265 3270 3275 3280 3285 3290 3295 3300 3305 3310 3315 3320 3325 3330 3335 3340 3345 3350 3355 3360 3365 3370 3375 3380 3385 3390 3395 3400 3405 3410 3415 3420 3425 3430 3435 3440 3445 3450 3455 3460 3465 3470 3475 3480 3485 3490 3495 3500 3505 3510 3515 3520 3525 3530 3535 3540 3545 3550 3555 3560 3565 3570 3575 3580 3585 3590 3595 3600 3605 3610 3615 3620 3625 3630 3635 3640 3645 3650 3655 3660 3665 3670 3675 3680 3685 3690 3695 3700 3705 3710 3715 3720 3725 3730 3735 3740 3745 3750 3755 3760 3765 3770 3775 3780 3785 3790 3795 3800 3805 3810 3815 3820 3825 3830 3835 3840 3845 3850 3855 3860 3865 3870 3875 3880 3885 3890 3895 3900 3905 3910 3915 3920 3925 3930 3935 3940 3945 3950 3955 3960 3965 3970 3975 3980 3985 3990 3995 4000 4005 4010 4015 4020 4025 4030 4035 4040 4045 4050 4055 4060 4065 4070 4075 4080 4085 4090 4095 4100 4105 4110 4115 4120 4125 4130 4135 4140 4145 4150 4155 4160 4165 4170 4175 4180 4185 4190 4195 4200 4205 4210 4215 4220 4225 4230 4235 4240 4245 4250 4255 4260 4265 4270 4275 4280 4285 4290 4295 4300 4305 4310 4315 4320 4325 4330 4335 4340 4345 4350 4355 4360 4365 4370 4375 4380 4385 4390 4395 4400 4405 4410 4415 4420 4425 4430 4435 4440 4445 4450 4455 4460 4465 4470 4475 4480 4485 4490 4495 4500 4505 4510 4515 4520 4525 4530 4535 4540 4545 4550 4555 4560 4565 4570 4575 4580 4585 4590 4595 4600 4605 4610 4615 4620 4625 4630 4635 4640 4645 4650 4655 4660 4665 4670 4675 4680 4685 4690 4695 4700 4705 4710 4715 4720 4725 4730 4735 4740 4745 4750 4755 4760 4765 4770 4775 4780 4785 4790 4795 4800 4805 4810 4815 4820 4825 4830 4835 4840 4845 4850 4855 4860 4865 4870 4875 4880 4885 4890 4895 4900 4905 4910 4915 4920 4925 4930 4935 4940 4945 4950 4955 4960 4965 4970 4975 4980 4985 4990 4995 5000 5005 5010 5015 5020 5025 5030 5035 5040 5045 5050 5055 5060 5065 5070 5075 5080 5085 5090 5095 5100 5105 5110 5115 5120 5125 5130 5135 5140 5145 5150 5155 5160 5165 5170 5175 5180 5185 5190 5195 5200 5205 5210 5215 5220 5225 5230 5235 5240 5245 5250 5255 5260 5265 5270 5275 5280 5285 5290 5295 5300 5305 5310 5315 5320 5325 5330 5335 5340 5345 5350 5355 5360 5365 5370 5375 5380 5385 5390 5395 5400 5405 5410 5415 5420 5425 5430 5435 5440 5445 5450 5455 5460 5465 5470 5475 5480 5485 5490 5495 5500 5505 5510 5515 5520 5525 5530 5535 5540 5545 5550 5555 5560 5565 5570 5575 5580 5585 5590 5595 5600 5605 5610 5615 5620 5625 5630 5635 5640 5645 5650 5655 5660 5665 5670 5675 5680 5685 5690 5695 5700 5705 5710 5715 5720 5725 5730 5735 5740 5745 5750 5755 5760 5765 5770 5775 5780 5785 5790 5795 5800 5805 5810 5815 5820 5825 5830 5835 5840 5845 5850 5855 5860 5865 5870 5875 5880 5885 5890 5895 5900 5905 5910 5915 5920 5925 5930 5935 5940 5945 5950 5955 5960 5965 5970 5975 5980 5985 5990 5995 6000 6005 6010 6015 6020 6025 6030 6035 6040 6045 6050 6055 6060 6065 6070 6075 6080 6085 6090 6095 6100 6105 6110 6115 6120 6125 6130 6135 6140 6145 6150 6155 6160 6165 6170 6175 6180 6185 6190 6195 6200 6205 6210 6215 6220 6225 6230 6235 6240 6245 6250 6255 6260 6265 6270 6275 6280 6285 6290 6295 6300 6305 6310 6315 6320 6325 6330 6335 6340 6345 6350 6355 6360 6365 6370 6375 6380 6385 6390 6395 6400 6405 6410 6415 6420 6425 6430 6435 6440 6445 6450 6455 6460 6465 6470 6475 6480 6485 6490 6495 6500 6505 6510 6515 6520 6525 6530 6535 6540 6545 6550 6555 6560 6565 6570 6575 6580 6585 6590 6595 6600 6605 6610 6615 6620 6625 6630 6635 6640 6645 6650 6655 6660 6665 6670 6675 6680 6685 6690 6695 6700 6705 6710 6715 6720 6725 6730 6735 6740 6745 6750 6755 6760 6765 6770 6775 6780 6785 6790 6795 6800 6805 6810 6815 6820 6825 6830 6835 6840 6845 6850 6855 6860 6865 6870 6875 6880 6885 6890 6895 6900 6905 6910 6915 6920 6925 6930 6935 6940 6945 6950 6955 6960 6965 6970 6975 6980 6985 6990 6995 7000 7005 7010 7015 7020 7025 7030 7035 7040 7045 7050 7055 7060 7065 7070 7075 7080 7085 7090 7095 7100 7105 7110 7115 7120 7125 7130 7135 7140 7145 7150 7155 7160 7165 7170 7175 7180 7185 7190 7195 7200 7205 7210 7215 7220 7225 7230 7235 7240 7245 7250 7255 7260 7265 7270 7275 7280 7285 7290 7295 7300 7305 7310 7315 7320 7325 7330 7335 7340 7345 7350 7355 7360 7365 7370 7375 7380 7385 7390 7395 7400 7405 7410 7415 7420 7425 7430 7435 7440 7445 7450 7455 7460 7465 7470 7475 7480 7485 7490 7495 7500 7505 7510 7515 7520 7525 7530 7535 7540 7545 7550 7555 7560 7565 7570 7575 7580 7585 7590 7595 7600 7605 7610 7615 7620 7625 7630 7635 7640 7645 7650 7655 7660 7665 7670 7675 7680 7685 7690 7695 7700 7705 7710 7715 7720 7725 7730 7735 7740 7745 7750 7755 7760 7765 7770 7775 7780 7785 7790 7795 7800 7805 7810 7815 7820 7825 7830 7835 7840 7845 7850 7855 7860 7865 7870 7875 7880 7885 7890 7895 7900 7905 7910 7915 7920 7925 7930 7935 7940 7945 7950 7955 7960 7965 7970 7975 7980 7985 7990 7995 8000 8005 8010 8015 8020 8025 8030 8035 8040 8045 8050 8055 8060 8065 8070 8075 8080 8085 8090 8095 8100 8105 8110 8115 8120 8125 8130 8135 8140 8145 8150 8155 8160 8165 8170 8175 8180 8185 8190 8195 8200 8205 8210 8215 8220 8225 8230 8235 8240 8245 8250 8255 8260 8265 8270 8275 8280 8285 8290 8295 8300 8305 8310 8315 8320 8325 8330 8335 8340 8345 8350 8355 8360 8365 8370 8375 8380 8385 8390 8395 8400 8405 8410 8415 8420 8425 8430 8435 8440 8445 8450 8455 8460 8465 8470 8475 8480 8485 8490 8495 8500 8505 8510 8515 8520 8525 8530 8535 8540 8545 8550 8555 8560 8565 8570 8575 8580 8585 8590 8595 8600 8605 8610 8615 8620 8625 8630 8635 8640 8645 8650 8655 8660 8665 8670 8675 8680 8685 8690 8695 8700 8705 8710 8715 8720 8725 8730 8735 8740 8745 8750 8755 8760 8765 8770 8775 8780 8785 8790 8795 8800 8805 8810 8815 8820 8825 8830 8835 8840 8845 8850 8855 8860 8865 8870 8875 8880 8885 8890 8895 8900 8905 8910 8915 8920 8925 8930 8935 8940 8945 8950 8955 8960 8965 8970 8975 8980 8985 8990 8995 9000 9005 9010 9015 9020 9025 9030 9035 9040 9045 9050 9055 9060 9065 9070 9075 9080 9085 9090 9095 9100 9105 9110 9115 9120 9125 9130 9135 9140 9145 9150 9155 9160 9165 9170 9175 9180 9185 9190 9195 9200 9205 9210 9215 9220 9225 9230 9235 9240 9245 9250 9255 9260 9265 9270 9275 9280 9285 9290 9295 9300 9305 9310 9315 9320 9325 9330 9335 9340 9345 9350 9355 9360 9365 9370 9375 9380 9385 9390 9395 9400 9405 9410 9415 9420 9425 9430 9435 9440 9445 9450 9455 9460 9465 9470 9475 9480 9485 9490 9495 9500 9505 9510 9515 9520 9525 9530 9535 9540 9545 9550 9555 9560 9565 9570 9575 9580 9585 9590 9595 9600 9605 9610 9615 9620 9625 9630 9635 9640 9645 9650 9655 9660 9665 9670 9675 9680 9685 9690 9695 9700 9705 9710 9715 9720 9725 9730 9735 9740 9745 9750 9755 9760 9765 9770 9775 9780 9785 9790 9795 9800 9805 9810 9815 9820 9825 9830 9835 9840 9845 9850 9855 9860 9865 9870 9875 9880 9885 9890 9895 9900 9905 9910 9915 9920 9925 9930 9935 9940 9945 9950 9955 9960 9965 9970 9975 9980 9985 9990 9995 9999 10000 10005 10010 10015 10020 10025 10030 10035 10040 10045 10050 10055 10060 10065 10070 10075 10080 10085 10090 10095 10100 10105 10110 10115 10120 10125 10130 10135 10140 10145 10150 10155 10160 10165 10170 10175 10180 10185 10190 10195 10200 10205 10210 10215 10220 10225 10230 10235 10240 10245 10250 10255 10260 10265 10270 10275 10280 10285 10290 10295 10300 10305 10310 10315 10320 10325 10330 10335 10340 10345 10350 10355 10360 10365 10370 10375 10380 10385 10390 10395 10400 10405 10410 10415 10420 10425 10430 10435 10440 10445 10450 10455 10460 10465 10470 10475 10480 10485 10490 10495 10500 10505 10510 10515 10520 10525 10530 10535 10540 10545 10550 10555 10560 10565 10570 10575 10580 10585 10590 10595 10600 10605 10610 10615 10620 10625 10630 10635 10640 10645 10650 10655 10660 10665 10670 10675 10680 10685 10690 10695 10700 10705 10710 10715 10720 10725 10730 10735 10740 10745 10750 10755 10760 10765 10770 10775 10780 10785 10790 10795 10800 10805 10810 10815 10820 10825 10830 10835 10840 10845 10850 10855 10860

16 Jan 2008

2003240299

15

melting point of the active agent at atmospheric pressure.

7. A pharmaceutical composition according to claim 1 or claim 2 wherein the metastable deposit has a melting point that is from 2 to 30°C lower than the 5 melting point of the active agent at atmospheric pressure.

8. A pharmaceutical composition according to any one of claims 3 to 5 wherein the composition is contained in a chamber of a spray applicator device comprising a valve for delivering the composition from the chamber, a nozzle for 10 dispersing the composition as an aerosol and means for providing a metered dose of aerosol from the nozzle said composition being retained under pressure within the chamber so as to maintain said propellant in a liquid form.

9. A pharmaceutical composition according to any one of claims 1 to 8 15 wherein the composition comprises a volatile solvent and propellant and provides a single phase solution of the active agent.

10. A pharmaceutical composition according to claim 1 or claim 2 wherein the composition contains no propellant.

20 11. A pharmaceutical composition according to claim 1 wherein composition comprises a physiologically active agent with a saturated solubility in the volatile solvent of not less than 0.05% w/w.

25 12. A pharmaceutical composition according to claim 1 wherein the composition comprises a physiologically active agent with a molecular weight of less than 600 Daltons and a melting point less than 200°C.

30 13. A pharmaceutical composition according to claim 1 wherein the composition comprises a physiologically active agent selected from the group consisting of testosterone, MENT (7-methyl-19-testosterone), or a pharmaceutically acceptable salt or derivative thereof.

Y:\Louise\Acute\Species\135417\_speci 000108.doc

16 Jan 2008  
2003240299

16

14. A pharmaceutical composition according to any one of claims 1 to 13 wherein the composition comprises a volatile solvent selected from the group consisting of ethanol and isopropanol.

5 15. A pharmaceutical composition according to any one of claims 1 to 14 further comprising a gelling agent in an amount of from 0.1% to 20% by weight of the total pharmaceutical composition.

10 16. A pharmaceutical composition according to claim 15 wherein the gelling agent is a cellulose derivative.

17. A pharmaceutical composition according to claim 16 wherein the gelling agent is selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl-methyl cellulose, hydroxyethyl cellulose, and mixtures thereof.

15 18. A pharmaceutical composition according to claim 15 wherein the gelling agent is an acrylic acid polymer.

20 19. Use of a volatile solvent and a physiologically active agent in the preparation of a spray on transdermal pharmaceutical composition of the active by formulating with the volatile solvent so that the composition when applied to the skin of a subject forms a metastable deposit of the active agent upon evaporation of the volatile solvent whereby partitioning of the physiologically active agent from the stratum corneum to the viable epidermis is enhanced.

25 20. A method for the transdermal delivery of a physiologically active agent to a subject in need thereof, comprising applying to the skin of the subject a pharmaceutical composition comprising:

30 (i) from about 0.1% to about 10% by weight of one or more physiologically active agents; and  
(ii) from about 85% to about 99.8% by weight of a volatile carrier comprising one or more volatile pharmaceutically acceptable solvents selected from the group consisting of ethanol, isopropanol, chloroform and acetone, and mixtures thereof, and optionally, a propellant;

Y:\Louse\Acra\Species\735417.Spec000108.doc

wherein the composition is free of non-volatile penetration enhancers and

wherein, upon application and evaporation of the volatile solvent, the composition forms a metastable deposit comprising the active agent.

5

21. A method of treatment or prophylaxis of disease in a subject in need thereof by transdermal administration of a physiologically active agent, comprising applying to the skin of the subject a topical pharmaceutical composition comprising:

10

(i) from about 0.1% to about 10% by weight of one or more physiologically active agents; and

(ii) from about 85% to about 99.8% by weight of a volatile carrier comprising one or more volatile pharmaceutically acceptable solvents selected from the group consisting of ethanol, isopropanol, chloroform and acetone, and

15

mixtures thereof, and optionally a propellant;

wherein the composition is free of non-volatile penetration enhancers and

wherein, upon application and evaporation of the volatile solvent, the composition forms a metastable deposit comprising the active agent.



20

22. A pharmaceutical composition according to claim 1 substantially as hereinbefore described.



23. A method according to claim 20 or claim 21 substantially as hereinbefore

25 described.

1/2

**FIGURE 1****FIGURE 2**

2/2

**FIGURE 3****FIGURE 4**